Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer.

Although initially reported as an androgen-repressed gene in the rat prostate, the functional role of testosterone-repressed prostate message-2 (TRPM-2) in apoptosis remains undefined. Inhibition of castration-induced apoptosis by calcium channel blocker treatment in androgen-dependent Shionogi tumors resulted in the prevention of TRPM-2 gene up-regulation, suggesting that TRPM-2 is not directly androgen-repressed, but is regulated by apoptotic stimuli. The overexpression of the TRPM-2 gene in human androgen-dependent LNCaP prostate cancer cells by stable transfection rendered them highly resistant to androgen ablation in vivo. We then tested the efficacy of antisense TRPM-2 oligodeoxynucleotide (ODN) therapy in the Shionogi tumor model and demonstrated that the systemic administration of antisense TRPM-2 ODNs in mice bearing Shionogi tumors after castration resulted in a more rapid onset of apoptosis and time to complete regression, as well as a significant delay of emergence of androgen-independent recurrent tumors compared to control ODN treatment. Collectively, these findings illustrate that TRPM-2 is an antiapoptotic rather than an androgen-repressed gene that confers resistance to androgen ablation and thereby helps accelerate the progression to androgen independence.

[1]  M. Gleave,et al.  Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  M. Gleave,et al.  Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. , 1999, Cancer research.

[3]  M. Gleave,et al.  Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. , 1999, Cancer research.

[4]  P. Kantoff,et al.  Management of hormone refractory prostate cancer: current standards and future prospects. , 1998, The Journal of urology.

[5]  I. Leav,et al.  Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat. , 1998, The American journal of pathology.

[6]  K. Nath,et al.  Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. , 1998, Kidney international.

[7]  H. Miyake,et al.  Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer , 1998, Oncogene.

[8]  A. Rademaker,et al.  Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  Huiling He,et al.  Maintenance of Calcium Homeostasis in the Endoplasmic Reticulum by Bcl-2 , 1997, The Journal of cell biology.

[10]  E. Loukinova,et al.  Interaction of Apolipoprotein J-Amyloid β-Peptide Complex with Low Density Lipoprotein Receptor-related Protein-2/Megalin , 1997, The Journal of Biological Chemistry.

[11]  F. Jourdan,et al.  Clusterin/ApoJ expression is associated with neuronal apoptosis in the olfactory mucosa of the adult mouse. , 1997, Journal of cell science.

[12]  D. Cunningham,et al.  BCL-2 antisense therapy in patients with non-Hodgkin lymphoma , 1997, The Lancet.

[13]  T. McDonnell,et al.  Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+. , 1996, Oncogene.

[14]  Doriano Fabbro,et al.  Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase , 1996, Nature Medicine.

[15]  A. Bitonti,et al.  A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts. , 1996, Experimental cell research.

[16]  M E Rosenberg,et al.  Clusterin: physiologic and pathophysiologic considerations. , 1995, The international journal of biochemistry & cell biology.

[17]  M. Griswold,et al.  Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). , 1995, Cancer research.

[18]  Y. Lazebnik,et al.  Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE , 1994, Nature.

[19]  A. Bergh,et al.  Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat. , 1994, Cancer research.

[20]  L. Denis,et al.  Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer , 1993, Cancer.

[21]  L. French,et al.  Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus. , 1992, The Journal of clinical investigation.

[22]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[23]  M. Gleave,et al.  Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. , 1992, Cancer research.

[24]  M. Gleave,et al.  Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. , 1991, Cancer research.

[25]  C. Olsson,et al.  SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. , 1991, Kidney international.

[26]  S. Dudek,et al.  Prostatic ductal system in rats: regional variation in localization of an androgen-repressed gene product, sulfated glycoprotein-2. , 1991, Endocrinology.

[27]  N. Kyprianou,et al.  Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. , 1990, Cancer research.

[28]  A. Coldman,et al.  Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. , 1990, Cancer research.

[29]  N. Bruchovsky,et al.  Gene expression during the early phases of regression of the androgen-dependent Shionogi mouse mammary carcinoma. , 1988, Cancer research.

[30]  O. Blaschuk,et al.  Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. , 1983, The Journal of biological chemistry.

[31]  N. Bruchovsky,et al.  Classification of dependent and autonomous variants of shionogi mammary carcinoma based on heterogenous patterns of androgen binding , 1978, Cell.

[32]  L. Perlaky,et al.  Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. , 1994, Oncology research.

[33]  S. Crooke.  Therapeutic Applications of Oligonucleotides , 1992, Bio/Technology.

[34]  N. Davidson,et al.  Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. , 1991, Cancer research.

[35]  M. Tenniswood,et al.  Androgen‐repressed messages in the rat ventral prostate , 1986, The Prostate.